SSTR5 and neoplasm: Pasireotide is a novel multi-receptor SSA with higher affinity to SSTR-5 compared with conventional SSAs, and has been used successfully in refractory insulinomas, presenting a potential management option in tumours under-expressing SSTR-2 receptors (Tirosh et al. 2016, Hendren et al. 2018, Siddiqui et al. 2020, Sileo et al. 2020, Bolanowski et al. 2022).